BTIG analyst Mark Massaro maintained a Buy rating on Exact Sciences (EXAS – Research Report) yesterday and set a price target of $65.00. The ...

Exact Sciences posted strong Q4 revenue growth but faced a significant EPS miss. Find out why I remain bullish on EXAS stock.

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that ...

Scotiabank raised the firm’s price target on Exact Sciences (EXAS) to $73 from $70 and keeps an Outperform rating on the shares. Exact’s Q4 was ...

Exact Sciences (NASDAQ:EXAS – Free Report) had its target price lifted by Scotiabank from $70.00 to $73.00 in a research note released on Monday,Benzinga reports. The brokerage currently has a sector ...

Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced better-than-expected revenue in Q4 CY2024, with sales ...

Two such candidates to consider right now are Etsy (NASDAQ: ETSY) and Exact Sciences (NASDAQ: EXAS), which are down 59% and ...

Operator Good day, everyone, and welcome to the Exact Sciences fourth quarter 2024 earnings call. Today's call is being ...

CIBC Asset Management Inc raised its holdings in Exact Sciences Co. (NASDAQ:EXAS – Free Report) by 14.0% in the fourth ...

Learn more about whether Exact Sciences Corporation or Twist Bioscience Corporation is a better investment based on AAII's A+ ...

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening ...

The company best known for its Cologuard colon cancer screening test posted a loss of $864.6 million, or $4.67 per share, on ...